Content
Week In Review: Gene Editing Scandal; Can China Biopharma Continue To Expand? News On Three China Life Science IPOs
Article By:
ChinaBio® Today
Read
Saturday, May 11, 2019 4:11 PM EDT
Regulatory changes are speeding drug development timelines for novel imported drugs in China, and VCs raised over $40 billion in new funding last year. Was 2018 as good as it gets, or can the growth in investment activity continue?
"This Is A Trainwreck" - Uber Opens Below IPO Price
Article By:
Tyler Durden
Read
Friday, May 10, 2019 12:20 PM EDT
this morning, faced with an ugly market background, Uber's indicative range has collapsed from around $48 to finally open at $42...popped, then traded back below the open.
Thoughts On Uber, Lyft, And The IPO Environment
Article By:
Interactive Brokers
Read
Friday, May 10, 2019 1:29 AM EDT
The IPO wave changed an important market dynamic. For several years we have seen a continual shrinkage in the supply of public equity, thanks to buybacks and takeovers. For now, that tide has turned.
The Uber IPO: What You Need To Know
This Is The Chart Uber's Bankers Don't Want You To See
Article By:
Tyler Durden
Read
Thursday, May 9, 2019 4:00 PM EDT
Contrary to the conventional wisdom about the "Amazon effect", companies that lose tons of money with no clear path to profitability actually haven't fared all that well in the public markets.
Uber’s IPO On Friday Could Put The Company’s Valuation At $91,5 Billion
Article By:
ForexNewsNow
Read
Wednesday, May 8, 2019 12:00 PM EDT
Uber, a ride-hailing application with over 110 million users in 173 countries, will have an IPO on Friday. The company has set the price range for its shares at $44 to $50.
MIT, Harvard Dive Into Cannabis Research; Facebook Goes Big On Crypto Payments
Article By:
Early Investing
Read
Monday, May 6, 2019 12:08 AM EDT
In the era when companies never seem to stop growing, what happens when a company ends up with more dead users than living? That's becoming a reality for Facebook. Also, a record raise for a cannabis company, and more startup, and crypto news.
Do You Fear The Fed?
Week In Review: Everest In-Licenses An ADC From Immunomedics In $835 Million Agreement, A China Record For A Single Asset
Article By:
ChinaBio® Today
Read
Saturday, May 4, 2019 5:44 PM EDT
Everest Medicines II of Shanghai, a C-Bridge company, agreed to pay up to a record $835 million in upfront and milestone payments for China rights to an Immunomedics ADC.
It's OK To Be Skeptical
Article By:
Roger Nusbaum
Read
Friday, May 3, 2019 10:33 PM EDT
Is the market actually growing to the sky? Or as dire as some others claim?
In this article: BYND
Beyond Meat Brings Home The Bacon
Article By:
Bespoke Investment Group
Read
Friday, May 3, 2019 8:07 PM EDT
While it’s hard to get excited about a stock that has so much optimism priced in already, we should note that BYND’s economics don’t actually look as bad as some other IPOs and businesses we have come across.
In this article: BYND
What Bulls And Bears Are Saying As BYND’s IPO Goes “Beyond” Parabolic
Article By:
Matt Weller
Read
Friday, May 3, 2019 12:25 PM EDT
BYND sits at the crossroads of several major secular trends, including fears about climate change, a focus on healthier eating, and the growing popularity of veganism/vegetarianism.